Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke, Fabienne Müller, Marina Keul, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, et al.
British Journal of Cancer (2019) Vol. 121, Iss. 9, pp. 725-737
Open Access | Times Cited: 1038
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro, Pasi A. Jänne, Tony Mok, et al.
Nature Cancer (2021) Vol. 2, Iss. 4, pp. 377-391
Closed Access | Times Cited: 361
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Alissa J. Cooper, Lecia V. Sequist, W. Marston Linehan
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 8, pp. 499-514
Open Access | Times Cited: 313
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Jingyi He, Zhengrong Huang, Linzhi Han, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 5
Open Access | Times Cited: 216
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Kai Fu, Fachao Xie, Fang Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 192
EGFR signaling pathway as therapeutic target in human cancers
Elena Levantini, Giorgia Maroni, Marzia Del Re, et al.
Seminars in Cancer Biology (2022) Vol. 85, pp. 253-275
Open Access | Times Cited: 185
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza, Ajaz Bulbul, John Paul Shen, et al.
Cancer Research (2019) Vol. 79, Iss. 4, pp. 689-698
Open Access | Times Cited: 182
Precision medicine in non-small cell lung cancer: Current applications and future directions
Soo‐Ryum Yang, Anne M. Schultheis, Helena A. Yu, et al.
Seminars in Cancer Biology (2020) Vol. 84, pp. 184-198
Closed Access | Times Cited: 173
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Andrew J. Piper‐Vallillo, Lecia V. Sequist, Zofia Piotrowska
Journal of Clinical Oncology (2020) Vol. 38, Iss. 25, pp. 2926-2936
Closed Access | Times Cited: 164
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, et al.
Journal of Thoracic Oncology (2019) Vol. 14, Iss. 10, pp. 1753-1765
Open Access | Times Cited: 147
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
Ruifang Dong, Miaolin Zhu, Mingming Liu, et al.
Pharmacological Research (2021) Vol. 167, pp. 105583-105583
Closed Access | Times Cited: 128
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 117
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 109
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Georgia Gomatou, Nikolaos Syrigos, Ηλίας Κοττέας
Cancers (2023) Vol. 15, Iss. 3, pp. 841-841
Open Access | Times Cited: 73
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Yuchu Xiang, Xudong Liu, Yifan Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 27
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, G.M. Marinato, C. Mulargiu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104295-104295
Open Access | Times Cited: 24
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Benjamin P. Brown, Yunkai Zhang, David Westover, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 11, pp. 3341-3351
Open Access | Times Cited: 99
The next tier of EGFR resistance mutations in lung cancer
Hannah L. Tumbrink, Alena Heimsoeth, Martin L. Sos
Oncogene (2020) Vol. 40, Iss. 1, pp. 1-11
Closed Access | Times Cited: 95
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
Xueli Tian, Tingxuan Gu, Mee‐Hyun Lee, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1877, Iss. 1, pp. 188645-188645
Closed Access | Times Cited: 86
Mechanisms of resistance to osimertinib
Chiara Lazzari, Vanesa Gregorc, Niki Karachaliou, et al.
Journal of Thoracic Disease (2020) Vol. 12, Iss. 5, pp. 2851-2858
Open Access | Times Cited: 81
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 593-593
Open Access | Times Cited: 67
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Andreas Koulouris, Christos Tsagkaris, Anna Chiara Corriero, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3337-3337
Open Access | Times Cited: 48
Acquired resistance mechanisms to osimertinib: The constant battle
Ziad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, et al.
Cancer Treatment Reviews (2023) Vol. 116, pp. 102557-102557
Closed Access | Times Cited: 39
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Juan Bautista Blaquier, Sandra Ortiz-Cuarán, Biagio Ricciuti, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3579-3591
Closed Access | Times Cited: 37
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top